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The vascular endothelial growth factor is produced
by a large variety of human tumors, including mela-
noma, in which it appears to play an important role
in the process of tumor-induced angiogenesis. Little
information is available on the role of placenta
growth factor, a member of the vascular endothelial
growth factor family of cytokines, in tumor angio-
genesis, even though placenta growth factor/vascular
endothelial growth factor heterodimers have been
recently isolated from tumor cells. To investigate the
role of placenta growth factor and vascular endothe-
lial growth factor homodimers and heterodimers in
melanoma angiogenesis and growth, 19 human mel-
anoma cell lines derived from primary or metastatic
tumors were characterized for the expression of
these cytokines and their receptors. Release of pla-
centa growth factor and vascular endothelial growth
factor polypeptides into the supernatant of human
melanoma cells was demonstrated. Reverse tran-
scriptase polymerase chain reaction analysis showed
the presence of mRNAs encoding at least three dif-
ferent vascular endothelial growth factor isoforms
(VEGF121, VEGF165, and VEGF189) and transcripts
for two placenta growth factor isoforms (PlGF-1 and
PlGF-2) in human melanoma cells. In addition, pla-
centa growth factor expression in human melanoma
in vivo was detected by immunohistochemical stain-
ing of tumor specimens. Both primary and meta-
static melanoma cells were found to express the
mRNAs encoding for vascular endothelial growth
factor and placenta growth factor receptors (KDR,
Flt-1, neuropilin-1, and neuropilin-2), and exposure
of melanoma cells to these cytokines resulted in a
speci®c proliferative response, supporting the
hypothesis of a role of these angiogenic factors in
melanoma growth. Key words: angiogenesis/melanoma
progression. J Invest Dermatol 115:1000±1007, 2000
T
he growth of solid tumors and the development of
metastases are greatly favored by the angiogenic
process. Actually, the vascular density of a number of
different types of primary tumors is predictive for
their metastatic potential (Gasparini, 1997). Several
factors produced by cancerous cells in¯uence the angiogenic
process (Folkman, 1995). Among them, the vascular endothelial
growth factor (VEGF) is produced by a variety of normal and
neoplastic cells and acts as an endothelial-cell-speci®c mitogen and
permeability factor (for review see Neufeld et al, 1999). At least ®ve
VEGF species of 121 (VEGF121), 145 (VEGF145), 165 (VEGF165),
189 (VEGF189), and 206 (VEGF206) amino acids are generated by
alternative mRNA splicing from a single gene (Neufeld et al, 1999)
and characterized by different biologic properties (Cohen et al,
1995; Poltorak et al, 1997).
Placenta growth factor (PlGF), a secreted dimeric protein of the
VEGF family, shares a 53% sequence identity with the platelet-
derived growth factor (PDGF)-like region of VEGF (Maglione et al,
1991). Similarly to VEGF, alternative splicing of PlGF mRNA
produces at least three polypeptides of 149 (PlGF-1), 170 (PlGF-2),
and 221 (PlGF-3) amino acids (Maglione et al, 1993; Cao et al,
1997). A highly basic 21 amino acid insertion in the carboxi-
terminal region of PlGF-2 sequence results in the high heparin-
binding af®nity of this polypeptide, whereas neither PlGF-1 nor
PlGF-3 bind heparin. PlGF has been detected in a limited number
of tissues and cell types (Clark et al, 1998) and its in vivo and in vitro
angiogenic activity has been demonstrated only recently (Ziche et al,
1997). Naturally occurring VEGF/PlGF heterodimers have also
been found in the supernatant of some tumor cell lines (DiSalvo
et al, 1995; Cao et al, 1996b). VEGF proangiogenic activity is
mediated by two tyrosine kinase receptors present on endothelial
cells: the 180 kDa fms-like tyrosine kinase (Flt-1) and the 200 kDa
kinase-insert-domain-containing receptor (KDR) (Neufeld et al,
1999). The binding of VEGF to KDR has been correlated with
endothelial cell proliferation (Millauer et al, 1993), whereas Flt-1
activation seems to result in the enhancement of cell migration
(Waltenberger et al, 1994; Barleon et al, 1996; Clauss et al, 1996).
The role of Flt-1 in other biologic activities triggered by VEGF is
still controversial. A soluble form of Flt-1 (sFlt-1), lacking part of
the extracellular domain, the transmembrane, and intracellular
regions (Kendall and Thomas, 1993), has been cloned. sFlt-1 binds
VEGF and inhibits its mitogenic activity in vascular endothelial
cells by impairing VEGF binding to KDR (Kendall et al, 1993).
PlGF shares with VEGF the capability to bind with high af®nity the
Flt-1 receptor (Sawano et al, 1996), whereas PlGF/VEGF
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heterodimers are also able to activate KDR (DiSalvo et al, 1995;
Cao et al, 1996b). More recently, VEGF165 and PlGF-2 have been
shown to bind also to neuropilin-1 and neuropilin-2, which
function as receptors for axon guidance factors of the semaphorin
family (Soker et al, 1998; Gluzman-Poltorak et al, 2000).
Nevertheless, both neuropilin receptors lack tyrosine kinase
activity, and binding of VEGF165 to porcine aortic endothelial
cells expressing only neuropilin-1 or neuropilin-2 did not affect cell
proliferation or migration (Soker et al, 1998; Gluzman-Poltorak
et al, 2000).
The role of VEGF in the process of tumor-induced angiogenesis
is well established (reviewed by Ferrara, 1995), and several studies
have focused on the intriguing possibility that VEGF could also
directly affect tumor cell proliferation. VEGF tyrosine kinase
receptors (Flt-1 and KDR) have been found in several human
tumor cells, such as ovarian carcinoma (Boocock et al, 1995),
AIDS-Kaposi sarcoma (Masood et al, 1997), prostate carcinoma
(Ferrer et al, 1999), colon carcinoma (AndreÂ et al, 2000), and
melanoma (Gitay-Goren et al, 1993; Graeven et al, 1999).
In a melanoma cell line, the expression of KDR receptor has
been correlated with a proliferative response to exogenously added
VEGF (Liu et al, 1995). In this report, however, the role played by
the other VEGF receptors as well as the production of PlGF by
melanoma cells were not analyzed. We were interested in studying
the possible role of PlGF in melanoma angiogenesis and
progression. To this end, we have characterized a wide variety of
primitive and metastatic human melanoma cell lines for the
expression of VEGF, PlGF, and their receptors, analyzed the in vivo
expression of PlGF in cutaneous melanomas, and evaluated the
effect of exogenously added VEGF and PlGF on melanoma cell
proliferation.
MATERIALS AND METHODS
Materials Culture media and supplements were purchased from
Euroclone (Oud-Beijerland, Holland), except for the 0.85 g per liter
NaHCO3/minimum essential medium to grow WM115 cells, which was
obtained from Gibco/BRL (Paisley, U.K.). Insulin-transferrin-sodium
selenite medium supplement (ITS) and heparin were from Sigma (St. Louis,
MO). Fatty-acid-free bovine serum albumin (BSA) was from Boehringer
Mannheim (Mannheim, Germany). VEGF and PlGF homodimers and
heterodimers used as standards in the enzyme-linked immunosorbent assay
(ELISA) and as stimuli in the mitogenic assays were from R&D Systems
(Abingdon, U.K.); rhVEGF165 homodimer was expressed and puri®ed
from Sf21 insect cells; PlGF-1 was expressed in Escherichia coli; VEGF/PlGF
heterodimer was originated by expression in E. coli of VEGF165 and PlGF-
1, followed by in vitro dimerization. Goat antibodies used in the ELISA
analysis (R&D Systems) recognized all the VEGF or PlGF isoforms. The
monoclonal antibodies used to neutralize VEGF (MAB 293) or PlGF
(MAB 264) stimulated cell growth were also from R&D Systems. The goat
polyclonal antibody raised against human PlGF and utilized for the
immunohistochemical analysis was from Santa Cruz Biotechnology (Santa
Cruz, CA).
Cell lines and normal human cells Nineteen human melanoma cell
lines of primary or metastatic origin were used. Six were established in our
laboratory (GR-Mel, ST-Mel, SN-Mel, PR-Mel, CN-Mel, and
TVMBO). SK-Mel-28 (Shiku et al, 1976), WM115, and WM266-4
(Satyamoorthy et al, 1997) were purchased from the American Type
Culture Collection (ATCC, Rockville, MD), and the remaining cell lines
were generous gifts from other laboratories: 13443-Mel (Colombo et al,
1992) from Dr. G. Parmiani (Istituto Nazionale Tumori, Milan, Italy); PD-
Mel, PNP-Mel, PNM-Mel, LCP-Mel, LCM-Mel, and GL-Mel from Dr.
F. Guadagni (Istituto Regina Elena, Rome, Italy); M14 (Golub et al, 1976)
from Dr. G. Zupi (Istituto Regina Elena); LB-24 (Wolfel et al, 1993) and
397-Mel (Topalian et al, 1989) from Dr. T. Boon (Ludwig Institute for
Cancer Research, Brussels, Belgium). Melanoma cell lines were maintained
in RPMI 1640 medium supplemented with 10% fetal bovine serum, 2 mM
glutamine, and 50 mg per ml gentamycin, except for the ATCC cell lines
WM115 and WM266-4, which were kept in culture as suggested by the
supplier. Five of these cell lines were obtained from primary tumors (GR-
Mel, ST-Mel, WM115, LCP-Mel, and PNP-Mel), six from cutaneous
metastases (SN-Mel, PR-Mel, M14, 397-Mel, LB-24, and WM266±4),
and eight originated from noncutaneous metastases, including lymph nodal
and organ tissue metastases (CN-Mel, PD-Mel, 13443-Mel, PNM-Mel,
LCM-Mel, GL-Mel, SK-Mel-28, and TVMBO).
Normal human melanocytes were isolated from human skin biopsies at
the IDI-IRCCS laboratory of Dr. M. De Luca (Pomezia, Italy) and in our
own laboratory, as previously described (De Luca et al, 1988), NIH/3T3
murine ®broblasts and RAJI (human Burkitt's lymphoma) cells were
purchased from the ATCC, and the human microvascular endothelial cell
line HMEC-1 was a generous gift of Dr. F.J. Candal (Centers of Disease
Control and Prevention, Atlanta, GA) (Ades et al, 1992). Normal human
keratinocytes were obtained from foreskins of healthy males, and cultured
on a feeder layer of lethally irradiated 3T3-J2 murine ®broblasts (a gift from
Dr. H. Green, Harvard Medical School, Boston, MA), as previously
described (Zambruno et al, 1995).
Preparation of conditioned medium and cell extracts for
quanti®cation of VEGF and PlGF polypeptides Conditioned
media from human melanoma cells and normal human melanocytes in
culture were obtained by incubating semicon¯uent cell cultures for 24 h in
0.1% BSA/RPMI medium without fetal bovine serum. These conditions
did not signi®cantly affect cell viability, and the percentage of adherent cells
was maintained between 93% and 99%. Supernatants were concentrated at
least 10-fold in Centriplus concentrators (Amicon, Beverly, MA). Cells
were detached from the ¯asks with phosphate-buffered saline (PBS)/
ethylenediamine tetraacetic acid (EDTA) or, when necessary, with trypsin/
EDTA. Cytokine secretion values were normalized by the total number of
cells. To quantify unreleased VEGF or PlGF, cell extracts were prepared by
washing cells once in PBS and resuspending them in lysis buffer (20 mM
Tris-HCl, 150 mM NaCl, 1 mM AEBSF, 1% Nonidet P-40, pH 8.0). After
30 min of incubation on ice, cell lysates were centrifuged and supernatants
were directly used for ELISA analysis.
ELISA Quanti®cation of the amount of VEGF and PlGF homodimers
and heterodimers in the conditioned medium and cell extracts was
performed as previously described (Harlow and Lane, 1988) using goat
anti-VEGF or anti-PlGF IgGs (R&D Systems) at a concentration of 10 mg
per ml in PBS to coat Maxisorp Nunc immunoplates (Nunc, Roskilde,
Denmark). Detection of the cytokines was performed with biotinylated
goat anti-VEGF or anti-PlGF IgGs (R&D Systems) and streptavidin-
alkaline phosphatase conjugate (1:10,000) (Boehringer Mannheim). For the
detection of VEGF/PlGF heterodimers, plates were coated with anti-
VEGF antibody and detection was carried out with biotinylated goat anti-
PlGF IgGs. The reaction was stopped and optical density at 405 nm was
measured in a Microplate reader 3550-UV (Bio-Rad, Hercules, CA). This
assay allowed detection of VEGF and PlGF polypeptides at concentrations
equal to or greater than 100 pg per ml.
Immunohistochemical analysis Sections of melanoma specimens
4 mm thick were deparaf®nized, rehydrated, and treated for 20 min with
0.3% H2O2 in PBS. Sections were preincubated with 3% BSA/PBS for 1 h,
and then incubated with the C-20 anti-PlGF antibody (Santa Cruz
Biotechnology) at a concentration of 4 mg per ml for 2 h at room
temperature in 3% BSA/PBS. Specimens were subsequently treated for
45 min with biotinylated antigoat IgGs (1:150) (Vector Laboratories,
Burlingame, CA) diluted in 3% BSA/PBS, and with peroxidase-conjugated
avidin (Vectastain Elite ABC kit, Vector Laboratories) for 1 h.
Immunoreactivity was visualized by peroxidase reaction, using 3-amino-
9-ethyl carbazole (AEC, Vector Laboratories) in H2O2 as substrate, and
specimens were counterstained with hematoxylin. Negative controls were
obtained by omitting the primary antibody. In a previous analysis on PlGF
expression during wound healing (Failla et al, 2000) we demonstrated the
suitability of the Santa Cruz polyclonal antibody sc-1880 (C-20) for
immunohistochemistry, checking its speci®city by Western blotting against
human recombinant VEGF and PlGF, and con®rming the data by in situ
hybridization analysis.
The study was approved by the Ethical Committee of the Istituto
Dermopatico dell'Immacolata, IDI-IRCCS, Rome, Italy.
Reverse transcriptase polymerase chain reaction (RT-PCR) Total
cellular RNA from the different cell lines and cultured normal human cells
(melanocytes and keratinocytes) was prepared using an RNeasy Midi kit
from Qiagen (Hilden, Germany), following the manufacturer's directions.
Three micrograms of total RNA per sample were used for reverse
transcription by the AMV enzyme (Boehringer Mannheim), for 60 min at
42°C, in 25 ml. Five microliters of this cDNA preparation were used for
each PCR ampli®cation reaction by 1 U of Dynazyme II DNA polymerase
(Finnzymes OY, Espoo, Finland), utilizing the following primers and
annealing conditions: forward primer 5¢-CCATGAACTTTCCTG-
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CTGTCTT-3¢ and reverse primer 5¢-TCACCGCCTCGGCTTGTC-3¢
for VEGF (annealing for 30 s at 60°C); forward primer 5¢-CTCCTA-
AAGATCCGTTCTGG-3¢ and reverse primer 5¢-GGTAATAAATAC-
ACGAGCCG-3¢ for PlGF (annealing for 30 s at 55°C); forward primer 5¢-
CACAGGAAACCTGGAGAATCAGACGACAAG-3¢ and reverse
primer 5¢-TGGTCGACCATGACGATGGACAAGTA-3¢ for KDR
(annealing for 1 min at 58°C); forward primer 5¢-GAAGGAAGGGAG-
CTCGTCATTC-3¢ and reverse primer 5¢-TACCATATGCGGTACAA-
GTCAGG-3¢ for the extracellular Flt-1 region (annealing for 1 min at
60°C); forward primer 5¢-CAAGTGGCCAGAGGCATGGAGTT-3¢ and
reverse primer 5¢-GATGTAGTCTTTACCATCCTGTTG-3¢ for the Flt-
1 carboxi-terminal end (annealing for 1 min at 60°C); forward primer 5¢-
ATGGAGAGGGGGCTGCCG-3¢ and reverse primer 5¢-CTATCGCG-
CTGTCGGTGTA-3¢ for neuropilin-1 (annealing for 30 s at 52°C);
forward primer 5¢-ATGGATATGTTTCCTCTCACC-3¢ and reverse
primer 5¢-GTCCAGCCAATCGTACTTGC-3¢ for neuropilin-2
(annealing for 30 s at 55°C). RNA integrity and the correct reverse
transcription of the samples were assessed by testing each cDNA
preparation for the ampli®cation of the housekeeping gene
glyceraldehyde-phosphate dehydrogenase (GAPDH). Controls were
performed excluding AMV reverse transcriptase from the reactions.
Ampli®cation products obtained after RT-PCR were puri®ed using the
QIAquick gel extraction kit (Qiagen), and sequenced using the dye
terminator cycle sequencing kit, in an Applied Biosystems PRISM 377
DNA Sequencer (Perkin Elmer, Foster City, CA).
Mitogenic assay The capability of VEGF and PlGF homodimers and
heterodimers to stimulate human melanoma cell growth was tested by
measuring cellular methyl-3[H]-thymidine uptake or by counting the
number of cells following incubation with these growth factors. For the
methyl-3[H]-thymidine uptake experiments, cells were seeded on 96-well
plates (3 3 103±5 3 103 cells per well, depending on the cell line), in 100 ml
of complete RPMI medium, and kept overnight at 37°C in a CO2
incubator. Subsequently, medium was changed with serum-free RPMI
containing 0.1% BSA and cells were maintained at 37°C for two further
days. Medium was then replaced with RPMI containing 0.1% BSA, 1 mg
per ml heparin, and one of the growth factors or the medium supplement
ITS, in quadruplicate samples. Samples with only BSA/heparin medium
were included to determine basal radioactivity uptake. After 15 h
incubation, 1 mCi of methyl-3[H]-thymidine (73 Ci per mmol,
Amersham, Buckinghamshire, U.K.) was added to each well, and the
plates were further incubated for 5 h. Labeled cells were transferred to
Uni®lter GF/C microplates (Canberra Packard, Meriden, CT) and the
excess of nonincorporated thymidine was washed out, using a Filtermate
196-cell harvester (Canberra Packard). Radioactivity retained in the ®lter
plates was then counted in a Top-Count microplate scintillation counter
(Canberra Packard). The speci®c inhibition of VEGF- or PlGF-induced
methyl-3[H]-thymidine uptake was performed by preincubating these
cytokines or ITS (as negative control) with the respective monoclonal
antibodies, for 1 h at room temperature. Preincubation of the cytokines
with a control monoclonal antibody (anti-HLA DP from Becton &
Dickinson, San Jose, CA) was carried out simultaneously.
For direct cell number counting, cells were seeded in 24-well plates
(2 3 104 cells per well), allowed to attach to the plastic overnight, and
serum-starved in 0.1% BSA/RPMI for 24 h before stimulation. Stimuli
(10 ng per ml of the cytokines and 5 mg per ml ITS as control) were added
in the presence of 1 mg per ml heparin in 0.1% BSA/RPMI. Seventy-two
hours after the addition of the different cytokines, cells were detached from
the plate by incubating with PBS/EDTA, and viable cells were counted.
RESULTS
In vitro secretion of VEGF and PlGF homodimers and
VEGF/PlGF heterodimers by human melanoma cells Cell
culture supernatants were collected to quantify, in an enzyme-
linked immunoassay, the amount of VEGF and PlGF homodimers
and VEGF/PlGF heterodimers secreted by different human
melanoma cell lines (Table I). Normal human keratinocytes,
secreting both VEGF and PlGF polypeptides (Ballaun et al, 1995;
Failla et al, 2000), were used as positive control, and mouse NIH/
3T3 ®broblasts were employed as negative control.
VEGF homodimers (VEGF/VEGF) were detected in the
supernatant of all the metastatic melanoma cell lines, at concentra-
tions ranging between 298 and 5743 pg per 106 cells. Among the
primary melanoma cells, three out of ®ve cell lines (ST-Mel, LCP-
Mel, and PNP-Mel) secreted VEGF at levels ranging between 1000
and 1800 pg per 106 cells, whereas the other two cell lines did not
release (WM115) or released extremely low levels (GR-Mel) of
VEGF/VEGF. PlGF homodimers (PlGF/PlGF) were also secreted
by human melanoma cells (Table I), although at lower levels than
VEGF/VEGF. In 10 out of 14 metastatic cell lines PlGF/PlGF
were released at concentrations ranging from 22 to 454 pg per 106
cells. On the other hand, only two out of ®ve cell lines from
primary melanomas secreted medium to low levels of PlGF (PNP-
Mel, 152 pg per 106 cells, and LCP-Mel, 19 pg per 106 cells).
VEGF/PlGF heterodimers were detected in the supernatant of
human melanoma cells as well (Table I), following the pattern of
PlGF secretion. As VEGF is generally produced in large amounts
by melanoma cells, the PlGF synthesis level could represent the
limiting factor for heterodimer assembly. Among the melanoma
cell lines utilized here, three pairs of cell lines from primary and
metastatic tumors from the same patient were analyzed. The
WM115 cell line (originated from the primary tumor of a patient
showing the ®rst metastases 9 mo after removal of the primary
lesion) did not release detectable VEGF or PlGF homodimers. Its
metastatic counterpart, the WM266-4 cell line, obtained from a
skin metastasis 18 mo later, secreted the highest levels of VEGF and
PlGF homodimers and heterodimers. Otherwise, when primary
and metastatic tumors were surgically removed simultaneously (cell
line pairs LCP-Mel/LCM-Mel and PNP-Mel/PNM-Mel), levels
of VEGF and PlGF released by cell lines from the primary lesions
and their metastatic counterparts did not differ substantially.
Neither PlGF/PlGF nor VEGF/PlGF were detected in the
Table I. Release of VEGF homodimer, PlGF homodimer,
and VEGF/PlGF heterodimer by human melanoma cells
and normal human melanocytes in culture
VEGF/VEGFa VEGF/PlGFa PlGF/PlGFa
Controls
NIH/3T3 NDb (5)c ND ND
Keratinocytesd 422 6 36 (3) 50 6 11 106 6 5
Melanocytes
MK54 ND (3) ND ND
MK57 54 6 31 (4) ND ND
MK291 ND (3) ND ND
Primary melanomas
GR-Mel 10 6 10 (4) ND ND
ST-Mel 1842 6 276 (5) 9 6 6 ND
WM115 ND (4) 71 6 20 ND
LCP-Mel 1563 6 263 (5) ND 19 6 7
PNP-Mel 1030 6 146 (4) 176 6 30 152 6 13
Cutaneous metastatic melanomas
PR-Mel 325 6 62 (4) 32 6 11 38 6 14
SN-Mel 759 6 66 (4) 22 6 11 5 6 5
M14 635 6 56 (6) 5 6 5 ND
397-Mel 1052 6 155 (4) 45 6 15 81 6 12
LB-24 298 6 31 (4) 205 6 18 335 6 46
WM266-4 5743 6 599 (3) 1142 6 5 454 6 77
Noncutaneous metastatic melanomas
TVMBO 3570 6 475 (4) 100 6 34 117 6 16
PD-Mel 628 6 68 (4) ND ND
13443-Mel 792 6 116 (4) 148 6 26 293 6 58
LCM-Mel 2338 6 387 (4) 27 6 9 22 6 6
PNM-Mel 608 6 11 (4) 97 6 9 114 6 14
GL-Mel 1224 6 74 (4) 23 6 3 66 6 12
CN-Mel 1691 6 102 (4) 8 6 5 5 6 5
SK-Mel-28 598 6 72 (4) 100 6 29 82 6 16
aValues are expressed as pg per 106 cells, as measured by the enzyme linked
immunoassay described under Materials and Methods, and represent the arithmetic
mean 6 the standard error of the mean.
bND, not detectable.
cThe number of independent determinations is given in parentheses.
dThe results represent the arithmetic mean 6 the standard error of the mean for
three different cultures of human keratinocytes.
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supernatant of cultured melanocytes from three different healthy
donors (Table I), and only one of them released quite low levels of
VEGF/VEGF (54 pg per 106 cells). The possibility that culture
conditions could affect VEGF and/or PlGF secretion levels was
further analyzed. Similar amounts of PlGF/PlGF or VEGF/PlGF
were secreted by melanoma cells cultured in the presence or the
absence of serum or in the melanocyte culture medium (data not
shown). Levels of VEGF/VEGF released, however, were increased
up to 50% when cells were maintained in the presence of serum or
in the melanocyte culture medium, compared with cells cultured in
0.1% BSA/RPMI (data not shown).
Detection of VEGF and PlGF isoforms expressed by human
melanoma cells VEGF and PlGF isoform expression was
analyzed in human melanoma cells by RT-PCR, and the
patterns obtained were compared with those of the positive
control normal human keratinocytes (Fig 1). NIH/3T3 cells were
used as negative control. The pattern obtained in human melanoma
cells included the same four bands shown in human keratinocytes
(Fig 1): VEGF121 (442 bp), VEGF165 (575 bp), VEGF189 (647 bp),
and an additional unidenti®ed 514 bp fragment. The size of this
band indicated that it could correspond either to VEGF145, which
contains the exons 1±5, 6a, and 8 (Poltorak et al, 1997), or to an
artifactual heteroduplex DNA formed from the VEGF121 and
VEGF165 ampli®cation products during PCR ampli®cation
(Eckhart et al, 1999). Surprisingly, VEGF transcript expression
was also strong in the cell line GR-Mel, which secreted almost
undetectable amounts of VEGF/VEGF and did not release VEGF/
PlGF. The ampli®cation products corresponding to the two major
isoforms, VEGF121 and VEGF165, were also faintly detected in one
of the normal melanocyte cultures (MK57).
PlGF isoforms were visualized as the 184 bp (PlGF-1) and 248 bp
(PlGF-2) ampli®cation products (Maglione et al, 1993). Both PlGF
transcripts were detected in all the 14 melanoma cell lines positive
for PlGF polypeptide secretion (Fig 2). Faint bands corresponding
to PlGF-1 and PlGF-2 mRNA were observed in ampli®cates from
three melanoma cell lines (ST-Mel, M14, and CN-Mel) that did
not release appreciable amounts of the protein, either as
homodimer or heterodimer, probably because of the lower
sensitivity of the ELISA with respect to RT-PCR detection.
Unexpectedly, GR-Mel cells, which do not release PlGF to the
culture medium, were positive for PlGF ampli®cates. RT-PCR
positivity for VEGF and PlGF in GR-Mel cells cannot be explained
by a delayed cytokine release, because after as long as 6 d of culture
VEGF and PlGF secretion was still undetectable (data not shown).
Accumulation of the protein into a cellular compartment could not
be detected in GR-Mel cell extracts (data not shown).
In vivo PlGF expression in human melanoma specimens To
verify that the PlGF expression we observed in melanoma cells was
not induced by culture conditions but was representative of the in
vivo situation, we analyzed primary as well as metastatic melanomas
by means of immunohistochemistry using an antihuman PlGF
antibody (Fig 2). Sixteen primary cutaneous melanoma specimens
(three, Breslow thickness < 0.75 mm; four, Breslow thickness
> 0.75±1.5 mm; four, Breslow thickness > 1.5±3.0 mm; ®ve,
Breslow thickness > 3.0 mm) and four skin metastases were
analyzed (Table II). A low percentage (< 20%) of PlGF-
immunopositive melanoma cells was detected in one out of three
primary tumors with Breslow thickness of 0.75 mm or less, whereas
in the other two no immunolabeled tumor cells could be scored
(Fig 1A). Cytoplasmic staining was observed in nine out of 13
primary tumors with Breslow thickness greater than 0.75 mm
(Fig 2B±D). These specimens showed different levels of
immunopositivity, in terms of staining intensity and percentage of
labeled tumor cells (see Table II). All the cutaneous metastases
analyzed displayed PlGF immunoreactivity (Fig 2E), although with
different levels of expression. Interestingly, staining was also
observed in the keratinocytes near melanoma cells, in both PlGF-
negative and PlGF-positive melanoma specimens (Fig 2A, E).
Expression of VEGF and PlGF receptor genes in human
melanoma cells The expression of receptors for VEGF and
PlGF (KDR, Flt-1, neuropilin-1, and neuropilin-2) in the 19
melanoma cell lines was evaluated by RT-PCR analysis. Figure 3
shows the results obtained for the tyrosine kinase receptors KDR
and Flt-1. Normal human keratinocytes and the human
microvasculature endothelial cell line HMEC-1 were used as
negative and positive controls. PCR ampli®cation of the KDR and
Flt-1 cDNAs coding for the receptor extracellular domains resulted
in the visualization of a 412 bp fragment and a 927 bp fragment,
respectively. None of the three normal melanocyte cultures
analyzed expressed either KDR or Flt-1 transcripts (two of them
are shown in Fig 3), whereas both KDR and Flt-1 mRNAs were
detectable in 16 out of the 19 melanoma cell lines tested. Among
the three remaining melanoma cell lines, only M14 cells were
negative for both receptors, whereas the PD-Mel cell line expressed
Flt-1 but not KDR, and LCP-Mel cells expressed KDR but not
Flt-1 transcript. The Flt-1 signal observed in Fig 4 might represent
the soluble form of this receptor (sFlt-1). Hence, RT-PCR
ampli®cation of a 497 bp fragment from the cDNA region coding
for the Flt-1 C-terminus was performed (Masood et al, 1997). Flt-1
mRNA expression was con®rmed in all but one of the melanoma
cell lines (i.e., LCM-Mel cells), in which Flt-1 molecules expressed
might therefore correspond to the soluble form of this receptor
(data not shown).
Figure 4 shows the results relative to neuropilin-1 and
neuropilin-2 mRNA expression. HMEC-1 cells were included as
positive control for the expression of both receptors, and RAJI and
NIH/3T3 cells were used as negative controls for neuropilin-1 and
neuropilin-2, respectively (Fig 4). One of the melanocyte samples
presented a weak neuropilin-1 signal, whereas the ®ve cell lines
originating from primary melanomas, as well as 13 out of the 14 cell
lines from metastatic melanomas, were all positive. Similar results
were obtained for neuropilin-2.
Effect of VEGF165 and PlGF-1 homodimers and
heterodimers on human melanoma cell proliferation The
®nding that human melanoma cell lines secrete PlGF and VEGF
and express their receptors raises the possibility of an autocrine
stimulation loop. To test this hypothesis, melanoma cell growth in
response to exogenously added homodimeric or heterodimeric
forms of VEGF165 and PlGF-1 was evaluated. Growth factors were
used at a concentration of 20 ng per ml, and the effect on melanoma
methyl-3[H]-thymidine uptake was compared with that of the cell
growth supplement ITS (5 mg per ml). Figures 5(A) and 5(B) show
Figure 1. RT-PCR analysis of VEGF and PlGF isoform expression
by human melanoma cells. Primers described in Materials and Methods
were used to amplify cDNA obtained from each cell line. PCR for
GAPDH was performed using the same cDNA preparation, to con®rm
integrity of the RNA samples. PCR products were separated in 2% agarose
gels and a 100 bp DNA ladder (Gibco/BRL) was used as molecular weight
marker. Results are representative of three different experiments.
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the results obtained with four representative melanoma cell lines.
The absence of KDR and Flt-1 in M14 cells corresponded to the
unresponsiveness of these cells to the VEGF and/or PlGF dimers,
even if they expressed both neuropilin receptors and were
stimulated by ITS (Fig 5A). A 30%±50% increment in DNA
synthesis was observed when melanoma cells expressing KDR and
Flt-1 were stimulated by VEGF, PlGF, or PlGF/VEGF dimers
(Fig 5A), independently of the neuropilin-1 mRNA presence (i.e.,
GL-Mel cells). The stimulation rate obtained was in the same range
as that described for VEGF by Liu et al (1995). The speci®city of
the response to the cytokines was tested by preincubation with
antibodies anti-VEGF or anti-PlGF, which were then maintained
in the culture medium during the experiment (Fig 5B). A 70%
inhibition of VEGF response was obtained using the anti-VEGF
monoclonal antibody, whereas anti-PlGF monoclonal antibody
completely abolished the response to PlGF. Stimulation by ITS was
slightly modi®ed by treatment with the speci®c antibodies (anti-
VEGF and anti-PlGF, Fig 5B). Interestingly, a signi®cant reduction
(about 20%) in basal methyl-3[H]-thymidine uptake was observed
when GL-Mel cells were incubated with anti-PlGF antibody,
suggesting interference with an autocrine mechanism maintained
by the melanoma-cell-produced PlGF (Fig 5B). Conversely, anti-
VEGF antibodies did not signi®cantly affect basal cell growth
(Fig 5B), although the higher levels of endogenous VEGF retained
in cell compartments in melanoma cells (result not shown) could be
responsible for a reduced accessibility of VEGF proteins to the
antibody. Cell growth was also analyzed by counting viable cells
after 72 h in the presence of homodimeric or heterodimeric VEGF
and PlGF or in the presence of ITS (Fig 5C). The results con®rmed
the effect of VEGF and PlGF on melanoma cell proliferation, at
levels comparable to those achieved by ITS.
DISCUSSION
The ability of cutaneous melanoma to induce angiogenesis (Denijn
and Ruiter, 1993) and the critical role played by VEGF in
melanoma progression (Erhard et al, 1997; Marcoval et al, 1997;
Salven et al, 1997) are well established. By contrast, no data are
available on PlGF expression and function in cutaneous melanoma.
The practice of therapeutic inhibition of tumor angiogenesis,
however, requires a detailed de®nition of the different angiogenic
factors produced by tumor cells and an understanding of their
relative biologic activity. We therefore decided to de®ne the
patterns of expression of VEGF, PlGF, and their receptors in
human melanoma cell lines and to investigate whether these
cytokines might be involved in an autocrine loop of cell growth
stimulation. All but one of the human melanoma cell lines tested
secreted moderate to high levels of VEGF. Here, we describe the
expression in human melanoma cell lines of two PlGF isoforms
(PlGF-1 and PlGF-2), and the release of PlGF polypeptides in the
melanoma cell culture medium, as homodimer or heterodimer
with VEGF. PlGF release appeared to be more frequent among cell
lines derived from metastatic melanomas (ten of fourteen) than
among cell lines derived from primary tumors (two of ®ve, both of
which were obtained from patients in an advanced stage of the
disease, who had already developed lymph node metastases).
Moreover, three of three normal human melanocyte cultures were
Figure 2. In vivo PlGF expression in primary
melanoma and cutaneous metastases. (A) Pri-
mary cutaneous melanoma with a Breslow thick-
ness of 0.4 mm, negative for PlGF. Some
suprabasal keratinocytes in the epidermis show
PlGF cytoplasmic staining with a predominant
perinuclear localization (inset). (B) Primary cuta-
neous melanoma with a Breslow thickness of
2.7 mm, negative for PlGF. (C) Primary melano-
ma with a Breslow thickness of 5 mm, displaying
PlGF cytoplasmic staining of tumor cells. (D)
PlGF-positive melanoma cell nests in the deep
dermis from the tumoral lesion shown in (C). (E)
PlGF expression by tumor cells and epidermal
keratinocytes in a cutaneous melanoma metastasis.
Scale bar: 30 mm; inset in (A): 10 mm.
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negative for PlGF secretion. Differently from VEGF, PlGF
secretion levels were not affected by culture conditions.
We could also prove that PlGF expression was not induced by
culture establishment. Production of PlGF polypeptides was,
indeed, demonstrated by immunohistochemical analysis of mela-
noma tumors. The in vivo results suggest that PlGF expression may
be upregulated during melanoma progression, as already described
for cervical squamous cell carcinomas (Kodama et al, 1997) and
meningiomas (Donnini et al, 1999). Interestingly, a PlGF-speci®c
staining was observed, in vivo, in the epidermal keratinocytes
surrounding melanoma cells, both in primary tumors and in
cutaneous metastases. Similarities between the stroma of tumors
and wounds have led to the concept that the former may be
experienced by the organism as a never healing wound (Dvorak,
1986). As PlGF expression is induced in keratinocytes migrating to
cover the wound in vivo and is upregulated in vitro by cytokines
secreted during wound healing (Failla et al, 2000), our data further
support this hypothesis. The induction of PlGF expression in
keratinocytes may be due to cytokines secreted by the melanoma
cells themselves, and/or by the in¯ammatory in®ltrate near the
tumor lesion. Further analysis is required to clearly understand the
biologic signi®cance of this induction.
Several studies in the literature have focused on the presence in
human melanoma cells of the VEGF receptors KDR (Gitay-Goren
et al, 1993; Liu et al, 1995) and, more recently, Flt-1 (Graeven et al,
1999). In agreement with the previous reports, we demonstrated
KDR and Flt-1 cDNA expression in 17 and 18, respectively, of 19
melanoma cell lines, and their absence in in vitro cultures of human
melanocytes. Flt-1 upregulation in melanoma cell lines might lead
to activation of signal transduction pathways that partially differ
from those induced through KDR activation (Landgren et al,
1998). In addition, the coexpression of Flt-1 in PlGF-producing
melanoma cell lines raises the possibility that this cytokine might
affect melanoma cell biology either directly, through an autocrine
mechanism, or indirectly, through modulation of the VEGF
response.
Studies on the effect of exogenously added VEGF on melanoma
cell growth have shown contradictory results (Liu et al, 1995;
Graeven et al, 1999). In the experimental conditions used here, we
observed an increase in methyl-3[H]-thymidine uptake and cell
number following VEGF or PlGF stimulation, as both homodimers
or heterodimers, in several melanoma cell lines. This response
correlates with VEGF receptor expression. Discrepancy with the
results from Graeven et al could be related to differences in culture
conditions, e.g., maintenance of melanoma cell lines in the
presence of insulin or use of late passage cells (Graeven et al,
1999). The role initially played by VEGF and PlGF on melanoma
cell growth could be lost with time, by adaptation to in vitro growth
conditions.
At present, the ability of PlGF to trigger a mitogenic activity in
endothelial cells is also controversial. Some studies suggested that
PlGF might modulate VEGF response by forming VEGF/PlGF
heterodimers with biologic properties different from those of the
VEGF homodimer (Cao et al, 1996a) or by increasing VEGF
availability to the KDR receptor through its release from common
receptors (Flt-1, neuropilin-1, and neuropilin-2). Other studies
described a direct PlGF mitogenic activity on human endothelial
Table II. Expression of PlGF in cutaneous melanomaa
Specimen Type Breslow
thickness
Clark level PlGF immunoreactivity
11927/00 PM 0.3 mm II ±
16762/99 PM 0.4 mm II ±
12630/00 PM 0.6 mm II +/±
09890/00 PM 0.9 mm IV +/±
12711/99 PM 1.2 mm IV +
09713/00 PM 1.3 mm IV ±
12467/00 PM 1.4 mm IV +
10840/00 PM 1.6 mm IV +/±
10486/99 PM 2.5 mm IV +/±
13044/00 PM 2.6 mm IV +
12765/99 PM 2.7 mm IV ±
11521/00 PM 5 mm IV +
17630/99 PM 5 mm IV ++
20693/99 PM 7 mm IV +/±
11270/00 PM 8 mm IV ±





aPM, primary tumor; CM, cutaneous metastasis; ++, medium expression; +,
low expression; +/± barely detectable expression or a few melanoma cells stained.
Figure 3. RT-PCR analysis of KDR and Flt-1 receptor expression
by human melanoma cells. Primers described in Materials and Methods
were used to amplify cDNA obtained from each cell line. PCR for
GAPDH was performed using the same cDNA preparation to con®rm
integrity of the RNA samples. KDR and GAPDH PCR products were
separated in 2% agarose gels, and a 100 bp DNA ladder (Gibco/BRL) was
used as molecular weight marker. Flt-1 PCR was carried out using the
primers for the extracellular domain of this receptor, and the ampli®cation
products were run in 1.5% agarose gels. As molecular weight marker, a 1 kb
DNA ladder from Gibco/BRL was used. Results are representative of three
different experiments.
Figure 4. RT-PCR analysis of neuropilin-1 and neuropilin-2
expression by human melanoma cells. Primers described in Materials
and Methods were used to amplify cDNA obtained from each cell line. PCR
products for neuropilin-1 (NP-1) and neuropilin-2 (NP-2) were separated
in 1% agarose gels and 100 bp DNA ladders from Pharmacia and from
Gibco/BRL, respectively, were used as molecular weight markers.
GAPDH PCR products, obtained using the same cDNA preparation to
con®rm integrity of the RNA samples, were separated in 2% agarose gels,
and a 100 bp DNA ladder (Gibco/BRL) was used as molecular weight
marker. Results are representative of three independent experiments.
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cells (Ziche et al, 1997). Our results on melanoma cell stimulation
by PlGF might be ascribed either to the direct activation of Flt-1
receptor or to the augmented availability of the VEGF produced by
the melanoma cells themselves. The possibility of the establishment
of a VEGF and/or PlGF autocrine loop in melanoma cells and the
precise role played by PlGF in these cells are currently under study
in our laboratory.
Recently, the capability of neuropilin-1 and neuropilin-2 to
establish a receptor±ligand interaction with some VEGF and PlGF
isoforms has been described (Migdal et al, 1998; Soker et al, 1998;
Gluzman-Poltorak et al, 2000). Our study demonstrates neuropilin-
1 and neuropilin-2 expression in 18 and 19, respectively, of the 19
melanoma cell lines analyzed, but the cytokine-neuropilin inter-
action does not seem to lead to increased cell proliferation. In fact,
M14 cells (that lack KDR and Flt-1 but express neuropilin-1) were
not responsive to VEGF165, whereas GL-Mel cells (positive for
KDR and Flt-1 expression and negative for neuropilin-1) were
induced to proliferate by VEGF165 treatment. It is also worth
noting that a positive response was obtained using the PlGF-1
isoform, which binds with very low af®nity to neuropilins. The
role played by the binding of VEGF and PlGF to neuropilins,
however, and the interference of this binding with KDR and/or
Flt-1 activity, should be considered in further studies on melanoma
cell stimulation by these cytokines.
In conclusion, our data show that a cytokine of the VEGF
family, the PlGF, and the receptors neuropilin-1 and neuropilin-2
are expressed by human melanoma cells and support the hypothesis
of a role of VEGF and PlGF in melanoma growth and progression.
These ®ndings raise the possibility of designing therapeutic
strategies for human melanoma treatment aimed to speci®cally
target the VEGF and/or PlGF interactions with their receptors.
Note added in proof While this work was being considered for
publication, Graeven et al reported the in vitro expression and
secretion of PlGF, as well as neuropilin-1 expression, in eight
melanoma cell lines (this journal, July 2000, 115: 118±123). Our
data con®rm these ®ndings in a wider cell line number from
primary and metastatic melanomas, also demonstrating the in vivo
production of PlGF in melanoma specimens. In contrast to what is
reported by Graeven et al, who used a modi®ed MTT colorimetric
assay to measure cell proliferation and could not demonstrate a cell
response to PlGF, our experiments with methyl-[3H]-thimidine
uptake and direct cell counting have shown a proliferative effect of
PlGF on melanoma cells in culture.
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